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1056 The Journal of Thoracic and CardObjective: This prospective randomized study compares a porcine with a bovine
bioprosthesis in the aortic position with regard to hemodynamic performance during
exercise.
Methods: Between August of 2000 and December of 2002, 136 patients underwent
aortic valve replacement with the porcine Medtronic Mosaic (n  66) or the bovine
Carpentier-Edwards Perimount (n  70) bioprosthesis. Transthoracic echocardiog-
raphy was performed to assess hemodynamic and dimensional data preoperatively
and 10 months postoperatively; the latter follow-up included stress echocardiogra-
phy with treadmill exercise.
Results: At rest and during exercise (25 and 50 W), there was a significant difference
in mean pressure gradient between the bovine and the porcine valves with labeled
sizes 21 and 23, with superiority of the Perimount prosthesis. There was no
difference in effective orifice area and incidence of patient-prosthesis mismatch
among all sizes. The left ventricular mass index decreased significantly within 10
months postoperatively in the size 23 bovine group and the size 25 porcine group.
Conclusions: Our data show a significant superiority of pressure gradients for the
bovine bioprosthesis, especially with small valve sizes, when compared with the
porcine device, which is more distinctive during exercise.
The major concern when implanting a biologic heart valve prosthesis areprimary tissue failure after implantation and long-term hemodynamic per-formance. Most bioprostheses are made of either bovine pericardium or
porcine heart valve tissue. Both types have been shown to warrant satisfactory
hemodynamic results and tissue durability over 10 to 15 years. However, up to now,
no prospective randomized comparison of both valve types under stress conditions
has been available. Hence the aim of this study was to compare porcine and bovine
bioprostheses in a prospective randomized investigational series with regard to
differences in hemodynamic performance at rest and during exercise and postop-
erative left ventricular (LV) mass regression. The porcine valves are represented by
the Medtronic Mosaic bioprosthesis (Medtronic, Inc, Minneapolis, Minn), and the
bovine valves are represented by the Carpentier-Edwards Perimount bioprosthesis
(Baxter Healthcare Corp, Edwards Division, Santa Ana, Calif).
Methods
Patient Enrollment
Between August of 2000 and September of 2002, 139 patients given a diagnosis of aortic
stenosis or mixed lesion of the aortic valve required valve replacement and entered the study.
Patients with isolated aortic regurgitation, patients who underwent replacement of more than
one valve, or patients who already had a pre-existing prosthetic valve in another position were
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CDexcluded from enrollment. Patients undergoing other concomitant
procedures were permitted to enter the study. Preoperative ran-
domization was performed after each patient’s informed consent
was received by blindly choosing a closed envelope, which con-
tained a note for one of the valves studied. Thus, the patients either
received the Medtronic Mosaic (n 66; mean age at implantation,
76.1 years; 45.5% male subjects) or the Edwards Perimount (n 
70; mean age at implantation, 75.1 years; 40.0% male subjects)
bioprosthesis. The study was approved by the institutional ethics
committee. Preoperative and operative data of each group are
summarized in Tables 1 and 2. In t tests for independent samples,
the porcine and bovine groups did not differ significantly with
regard to sex, age, distribution of preoperative New York Heart
Association class, heart rhythm, aortic valve lesion, LV morphol-
ogy and function (Table 3), aortic crossclamp time, and valve size
distribution. The patients were examined preoperatively and 10
months (mean, 9.2  5.2 months) postoperatively, with the latter
investigation including transthoracic echocardiography at rest and
at stress by using treadmill exercise.
Exercise Protocol
During bicycle exercise, patients sat on a seat reclined in a 50°
position. The starting workload was 0 W and was then increased
by 25 W every 2 minutes. The patients were encouraged to
exercise until exhaustion. The test was stopped if there was no
increase or an abnormal increase in blood pressure (diastolic blood
TABLE 1. Preoperative data
Mosaic Perimount P value†
No. of patients 66 70
Age on implantation (y)*
Mean 76.1 5.3 75.1  5.6 .293
Range 65.7-89.5 60.1-87.8
Sex .524
Male 30 28
Female 36 42
Body surface area (m2)* 1.81 0.19 1.81 0.21 .922
Cardiac rhythm
Sinus rhythm 56 52
Atrial fibrillation 7 10
Heart block 2 2
Paced rhythm 1 6
NYHA classification
Class I 0 0
Class II 3 5
Class III 53 49
Class IV 10 16
Aortic valve lesion
Isolated stenosis 26 31
Stenosis and
regurgitation
40 39
Left ventricular mass
index (g/m2)*
184.5 70.9 179.9 68.5 .716
NYHA, New York Heart Association. *Results as means  SD. †t Test for
independent samples.pressure, 110 mm Hg), electrocardiographic evidence of isch-
The Journal of Thoracicemia (horizontal or downsloping S-T depression or S-T lifting),
significant arrhythmia (new atrial fibrillation or ventricular ar-
rhythmia), chest pain, vertigo, inadequate tachycardia, or inade-
quate dyspnea. To facilitate Doppler measurements during exer-
cise, the site on the chest where optimum Doppler wave forms had
been recorded was marked before starting exercise. In case of
unsatisfactory Doppler signals, the whole bicycle unit was tilted
slightly to the left side until optimal measurements were obtained.
Measurements were performed at the end of each 2-minute work-
load level. Blood pressure was measured noninvasively every
minute with a sphygmomanometer cuff fixed on the right arm. A
12-lead electrocardiogram was continuously recorded.
Echocardiographic Measurement
Echocardiographic measurements performed at rest included the
transvalvular flow velocity with continuous-wave Doppler scan-
ning and left ventricular outflow tract (LVOT) flow velocity with
TABLE 2. Operative data
Mosaic Perimount P value†
Valve size (labeled)
19 3 5
21 20 25
23 30 32
25 13 8
Average* 22.6 1.6 22.2 1.6 .170
Valve size index (mm/m2)* 12.6 1.2 12.4 1.3 .447
Aortic annulus diameter 22.6 1.8 22.6 1.7 .831
Concomitant procedures
None 33 35
CABG 30 33
Other 3 2
Aortic crossclamp time (min)*
Isolated procedures 61.2 15.2 62.0 14.8 .866
Combined procedures 81.7 19.1 89.3 26.1 .265
CABG, Coronary artery bypass grafting. *Results as means  SD. †t Test
for independent samples.
TABLE 3. Left ventricular morphology and function at late
follow-up
Mosaic Perimount P value*
End-diastolic dimension
(mm)
44.6 7.0 44.5 10.0 .944
End-systolic dimension
(mm)
33.6 8.2 33.3 9.7 .843
End-diastolic septum
thickness (mm)
11.4 2.9 11.9 2.2 .402
End-diastolic posterior
wall thickness (mm)
12.4 2.3 11.9 2.4 .278
Left ventricular mass (g) 256.0 107.4 250.7 99.9 .803
Left ventricular mass
index (g/m2)
142.1 55.8 136.2 50.1 .592
Fractional shortening (%) 24.9 11.1 25.8 9.7 .696Results are presented as means  SD. *t Test for independent samples.
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from a parasternal long-axis view. The same measurements were
performed during exercise, except for LVOT diameter, which was
assumed to remain constant.1 The velocity recording was first
performed in the transvalvular jet and then in the LVOT. From
these measurements, we calculated the LV stroke volume as the
product of LVOT velocity time integral and cross-sectional area
and the cardiac output as the product of stroke volume and heart
rate. The transvalvular pressure gradient was calculated by using
the modified Bernoulli equation, with inclusion of subvalvular
velocity and the effective orifice area (EOA) by using the standard
continuity equation. If the difference in heart rate between the time
of transvalvular velocity recording and that of LVOT velocity
recording was greater than 5%, the data were rejected to avoid
potential errors in EOA and mean gradient because of changing
hemodynamics. The EOA was indexed for body surface area.
LV end-systolic and end-diastolic dimensions and the thickness
of the LV posterior wall and interventricular septum were assessed
in the short axis of the parasternal view by means of multiple
M-mode measurements with calculation of shortening fraction. LV
mass was calculated by using the corrected formula of the Amer-
ican Society of Echocardiography and was indexed by body sur-
face area.2
TABLE 4, A. Hemodynamic results at rest grouped by labe
Parameter All
Mean pressure gradient (mm Hg)
Mosaic 14.6 5.0* 2
Perimount 11.4 4.1* 1
Effective orifice area (cm2)
Mosaic 1.49 0.52 0
Perimount 1.56 0.41 0
Effective orifice area index (cm2/m2)
Mosaic 0.84 0.31 0
Perimount 0.86 0.24 0
Results are presented as means  SD. *P  .05, t test for independent s
TABLE 4, B. Hemodynamic results at rest grouped by aort
Parameter 18-20
Mean pressure gradient (mm Hg)
Mosaic 19.2 7.6
Perimount 17.6 3.1
Effective orifice area (cm2)
Mosaic 0.89 0.22
Perimount 0.93 0.04
Effective orifice area index (cm2/m2)
Mosaic 0.53 0.14
Perimount 0.57 0.04Results are presented as means  SD. *P  .05, t test for independent sampl
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The Medtronic Mosaic is a stented heart valve fixed with glutar-
aldehyde at zero pressure and treated with -amino-oleic acid to
reduce tissue calcification. It has been in clinical use since 1994
(Europe) and 2000 (United States), respectively, and has shown
satisfactory hemodynamic performance and freedom rates from
adverse events.3-6 The Carpentier-Edwards Perimount is also a
stented heart valve fixed with glutaraldehyde at low pressure, and
the cusps are treated with surfactant to restrict calcification. The
Perimount received US Food and Drug Administration approval in
1991. Long-term studies have constantly shown excellent hemo-
dynamic and clinical results.7-10
Surgical Procedure
Aortic valve replacement was undertaken by using standard car-
diopulmonary bypass at mild hypothermia with cold crystalloid
cardioplegia. Intraoperatively, aortic annulus diameter was mea-
sured by the surgeon by inserting a Hegar dilator into the annulus.
Mean aortic annulus diameter was equal in the Mosaic and the
Perimount groups. Prosthetic valve size was determined by using
the original sizer provided by each manufacturer. The Mosaic
valve is designed to allow for a complete supra-annular implanta-
tion technique made possible by a low-profile stent design and a
valve size
Valve size
9 21 23 25
8.0 14.9  4.5* 13.8 4.4* 13.7  4.0
3.7 11.2  3.5* 10.9 4.3* 10.6  2.1
0.30 1.18 0.27 1.54 0.52 1.94  0.43
0.04 1.39 0.39 1.71 0.34 1.76  0.40
0.16 0.68 0.17 0.88 0.33 1.04  0.30
0.05 0.81 0.25 0.91 0.22 0.92  0.27
es.
nulus diameter
Aortic annulus diameter (mm)
21-22 23-24 25-26
14.9 4.9* 13.3 3.9 13.5  4.2
10.7 3.0* 10.9 4.5 10.6  2.1
1.36 0.39 1.59 0.54 1.95  0.45
1.47 0.39 1.70 0.34 1.76  0.40
0.77 0.23 0.90 0.36 1.06  0.32
0.84 0.25 0.91 0.22 0.92  0.27led
1
6.2
7.9
.74
.92
.45
.58ic anes.
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CDconstruction involving no stent material reaching into the aortic
annulus and disturbing the physiologic flow pattern. The Peri-
mount bioprosthesis is sized for and implanted in the intra-supra-
annular position. There was no difference in the operative tech-
nique between both valve types. The bioprostheses were implanted
with pledget-supported, interrupted, noneverting mattress sutures.
Statistical Analysis
Data are expressed as means  1 SD. Comparisons between both
groups were made by the t test for independent samples in case of
normal data distribution and the Mann-Whitney U test in case of
nonnormal data distribution. Comparisons within one group were
performed by using the t test for dependent samples or the Wil-
coxon matched pairs test, respectively. Correlations were tested
with the Pearson product-moment method. Because there were few
patients in the size 19 groups, no statistical comparison was
performed for this group.
Results
Hemodynamic Results at Rest
Mean systolic pressure gradient, EOA, and effective orifice
area index (EOAI) of the Mosaic and the Perimount valves
TABLE 5, A. Hemodynamic results at stress grouped by la
Size Valve
Rest 25
MPG SV MPG
All Mosaic 14.6 5.0* 83.1 23.3 18.2 5.8*
Perimount 11.4 4.1* 79.5 21.1 13.4 3.6*
19 Mosaic 26.2 8.0 54.8 15.0 28.4 9.0
Perimount 17.9 3.7 62.3 14.8 20.7 4.4
21 Mosaic 14.9 4.5* 71.4 14.8 19.4 6.4*
Perimount 11.2 3.5* 70.8 21.3 12.5 1.9*
23 Mosaic 13.8 4.4* 85.4 23.2 17.1 4.7*
Perimount 10.9 4.3* 88.7 20.1 13.2 3.5*
25 Mosaic 13.7 4.0 99.1 23.2* 17.1 5.3
Perimount 10.6 2.1 73.1 9.0* 13.0 2.9
Results are presented as means  SD. MPG, Mean pressure gradient; S
TABLE 5, B. Hemodynamic results at stress grouped by ao
Aortic
annulus Valve
25 W
MPG SV
18-20 Mosaic 22.0 7.4 67.3 16.2
Perimount 18.5 5.6 70.4 17.3
21-22 Mosaic 19.3 6.4* 84.0 21.9*
Perimount 12.8 2.2* 69.7 14.2*
23-24 Mosaic 16.1 3.9* 84.2 15.7
Perimount 13.0 3.6* 85.7 17.4
25-26 Mosaic 17.2 5.6 94.7 20.2
Perimount 13.0 2.9 92.2 13.7Results are presented as means  SD. MPG, Mean pressure gradient; SV, stro
The Journal of Thoracicafter 9.2  5.2 months at rest are depicted in Table 4, A,
grouped by labeled valve size and in Table 4, B, grouped by
aortic annulus diameter.
Hemodynamic Results at Stress
Mean systolic pressure gradients during treadmill exer-
cise are depicted in Table 5, A , grouped by labeled valve
size and by exercise level and in Table 5, B , grouped by
aortic annulus diameter. Additionally, the corresponding
mean stroke volume of each subgroup is shown to refer
potential differences in mean pressure gradient to differ-
ences in volume load. Exercise data are complete for 46
patients in the Perimount group and 47 patients in the
Mosaic group. Five patients died before late follow-up,
with death unrelated to the valves studied (Perimount, n
 3; Mosaic, n  2). Of the remaining 38 patients, 15
patients did not attend the follow-up examination because
of general morbidity. Data of 23 patients obtained during
exercise were excluded from statistical calculations be-
cause suboptimal sonic conditions did not allow reliable
echocardiographic measurements.
d valve size
50 W 75 W
SV MPG SV MPG SV
 20.1 21.8 5.6* 97.8 20.4 23.7 6.7 119.1 34.3*
 17.8 16.5 4.0* 86.6 17.7 20.1 5.9 99.1  19.6*
 17.4 18.8 72.5 — —
 20.6 26.4 2.4 63.5 14.4 — —
 18.3 22.5 6.0* 87.5 19.4 25.1 120.1
 12.4 15.4 2.2* 79.2 11.7 17.4 3.5 77.8  15.6
 18.8 22.6 5.4* 99.9 19.5 25.7 5.6 110.4 33.9
 16.7 17.0 3.6* 91.9 19.1 22.1 6.5 103.9 20.4
 19.1 19.6 5.8 108.5 18.3 20.2 8.0 133.5 35.9
 13.7 13.7 3.8 95.8 14.8 17.5 4.8 104.1 10.1
ke volume. *P  .05, t test for independent samples.
annulus diameter
50 W 75 W
MPG SV MPG SV
0.6 2.5 85.4  12.6 — —
2.9 6.3 68.9 13.8 20.8 83.0
3.7 6.3* 95.5  23.4 28.5 3.0* 129.2  30.7
5.4 2.2* 81.7  13.0 16.5 2.4* 88.3  27.2
0.6 4.5* 97.7 16.9 23.3 5.8 96.3  27.2
7.1 3.7* 91.3  20.1 22.6 6.8 102.6  21.3
9.9 6.0 108.0 19.3 20.2 8.0 133.5  35.9
3.7 3.8 95.8  14.8 17.5 4.8 104.1  10.1bele
W
84.3
79.6
56.0
68.2
76.5
67.4
87.0
86.0
94.2
92.2rtic
2
2
2
1
2
1
1
1ke volume. *P  .05, t test for independent samples.
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Patient-prosthesis mismatch is rated in 3 grades according
to the results in EOAI: no mismatch, EOAI greater than
0.85 cm2/m2; moderate mismatch, EOAI less than or equal
to 0.85 cm2/m2; and severe mismatch, EOAI less than or
equal to 0.65 cm2/m2.11 The incidence of patient-prosthesis
mismatch grouped by labeled valve size is shown in Table
6.
Left Ventricular Mass Regression
LV mass regression between preoperative echocardio-
graphic measurement and late follow-up (9.2 5.2 months)
is shown in Table 7 represented by the change in LV mass
index.
Discussion
Heart valve bioprostheses do not require constant anticoag-
ulant therapy because of lower thrombogenicity compared
with mechanical prostheses. However, the use of biopros-
thetic valves for heart valve replacement is restricted be-
TABLE 6. Incidence of patient-prosthesis mismatch
grouped by labeled valve size
Size Valve
Patient-prosthesis mismatch
No
(EOAI >0.85
cm2/m2)
Moderate
(EOAI <0.85
cm2/m2)
Severe
(EOAI <0.65
cm2/m2)
19 Mosaic 0% 0% 100%
Perimount 0% 0% 100%
21 Mosaic 15.4% 38.5% 46.2%
Perimount 40.0% 20.0% 40.0%
23 Mosaic 40.9% 36.4% 22.7%
Perimount 56.5% 30.4% 13.0%
25 Mosaic 70.0% 20.0% 10.0%
Perimount 60.0% 20.0% 20.0%
EOAI, Effective orifice area index.
TABLE 7. Postoperative left ventricular mass regression g
Size Valve Preoperati
All Mosaic 187.2 69
Perimount 175.8 52
19 Mosaic 233 63
Perimount 151.7 66
21 Mosaic 179.6 48
Perimount 192.7 71
23 Mosaic 185.7 78
Perimount 171.2 39
25 Mosaic 190.8 77
Perimount 162.6 30Results are presented as means  SD.
1060 The Journal of Thoracic and Cardiovascular Surgery ● Macause of the limited tissue durability. About 8 years after
implantation, bovine and porcine valves exhibit a clear
progression in the frequency of structural valve deteriora-
tion.12,13 Therefore, bioprostheses are mostly implanted in
patients older than 70 years of age, assuming that the
patient’s death precedes prosthetic failure. Within the group
of biologic heart valves, the most frequently used valves
consist of porcine heart valve tissue or of bovine pericardial
tissue. Both for the porcine and for the bovine bioprosthe-
ses, various investigational series have demonstrated satis-
factory hemodynamic and clinical performance. In particu-
lar, the analyzed devices of this study (Mosaic and
Perimount) have shown low mean pressure gradients, large
effective orifice areas, and high freedom rates from pros-
thesis-related adverse events in long-term studies.3-10 How-
ever, up to now, there has been no direct comparison be-
tween porcine and bovine bioprostheses within a
prospective randomized study design to analyze the hemo-
dynamic performance of both groups at rest and during
exercise. Obviously, results obtained at stress are by far
more suitable to investigate the performance of a valve type
than hemodynamic data obtained at rest.
Hemodynamic Data at Rest and at Stress
No statistical comparison was performed in the size 19
group because of the small number of patients enrolled.
Concerning the hemodynamic results at rest, there is a
significant superiority in mean pressure gradient of the
bovine bioprosthesis in general (P  .001) with valve sizes
21 (P .022) and 23 (P .031) compared with the porcine
valve sizes 21 and 23. No significant difference was found
in mean pressure gradient comparing valve size 25 (P 
.139), but an obvious trend toward lower pressure gradients
was seen in the bovine group. However, Vitale and col-
leagues14 and Bortolotti and associates15 reported on higher
pressure gradients with the size 19 and 21 Perimount valves.
ed by labeled valve size
Left ventricular mass index (g/m2)
Postoperative Reduction
139.1 56.7* 48.0  88.9
134.1 49.5* 41.8  67.2
131 6.1 98.6  57.2
136.8 25.2 15.0  49.7
151.5 56.2 28.2  69.9
139.6 68.4 53.2  92.1
142.0 67.8 43.7  104.5
131.2 41.2* 39.9  57.8
117.2 25.4* 73.6  77.7
128.5 39.0 34.1  29.9roup
ve
.4*
.7*
.3
.3
.4
.0
.9
.8*
.2*
.0y 2005
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again showed significantly lower mean pressure gradients
than the porcine valves, with even more distinct differences
(size 21, P  .0006 in 25 W and P  .0005 in 50 W; size
23, P  .002 in 25 W and P  .0007 in 50 W). In the size
19 and 25 groups, there is a trend towards better hemody-
namics in the bovine group but without significant results in
t tests for independent samples for the size 25 group (P 
.132 in 25 W and P  .061 in 50 W).
Mean pressure gradient was calculated according to the
modified Bernoulli formula, which is based on the blood
flow velocity measured by means of continuous Doppler
scanning at the prosthesis and by means of pulsed Doppler
scanning in the LVOT. To exclude differences in mean
pressure gradient between both investigated bioprostheses
caused by different levels of blood flow at the same level of
exercise, we added the mean stroke volume for each valve
size at each exercise level to the table of results. As depicted
in Table 4, there was no significant difference in the mean
stroke volume of the size 21 and 23 prostheses, which
differed significantly in mean pressure gradients. We pre-
ferred to refer the hemodynamic results at stress to the
stroke volume to omit bias caused by interindividual per-
formance levels during exercise. However, often cardiac
output (stroke volume  heart rate in milliliters per minute)
is used as a reference. We observed that old patients, in
particular, often increase their cardiac output, mainly by an
increase in heart rate and not by enhancing the stroke
volume. Finally, cardiac output increases during exercise,
with steady stroke volume. We think that the stroke volume
is the decisive parameter, which mainly influences the pres-
sure gradients, and therefore, the stroke volume is the most
suitable parameter as a reference value for comparisons of
hemodynamic data at stress.
It should be mentioned that the comparison of 2 biopros-
theses according to their labeled valve size is difficult be-
cause the labeled valve size does not represent the geomet-
ric dimensions of the valve. In general, the inner diameter of
the Mosaic prosthesis is smaller across all sizes than the
inner diameter of the Perimount prosthesis, whereas the
sewing ring diameter of the Mosaic valve is smaller in sizes
19, 21, and 23; equal in size 25; and larger in sizes 27 and
29 in comparison with that of the Perimount valve. More-
over, the Mosaic is intended for complete supra-annular
position and the Perimount for intra-supra-annular position.
For example, in the same aortic root either a size 21 Peri-
mount or a size 23 Mosaic prosthesis, allowing for lower
pressure gradients, might be implanted. However, this up-
sizing is not considered in a hemodynamic comparison
simply on the basis of labeled valve size. Such difficulties
must be considered when assessing the hemodynamic per-
formance of these prostheses and additionally must be re-
The Journal of Thoracicmembered in all comparisons between different heart valve
prostheses.16
For this reason, the hemodynamic results are additionally
depicted according to the patient annulus diameter, which
was measured intraoperatively by the cardiac surgeon (Ta-
bles 4, B, and 5, B). In this series the mean aortic annulus
diameter was identical for the Mosaic and the Perimount
groups (22.6 mm). The mean labeled valve size did not
differ significantly (Mosaic, 22.6 mm; Perimount, 22.2
mm), with a tendency toward larger valve sizes in patients
receiving Mosaic prostheses. These results do not confirm
the expectation that in general a Mosaic prosthesis larger in
labeled valve size can be implanted than a Perimount pros-
thesis. The fact that upsizing of the Mosaic valve is not
possible in all cases can be explained by looking at the
geometric dimensions of both prostheses. The sewing ring
diameter of the size 23 Perimount prostheses is 31 mm, the
sewing ring diameter of a size 23 Mosaic prosthesis is 30
mm, and the sewing ring diameter of a size 25 Mosaic
prosthesis is 33 mm. Therefore, an objective comparison of
the hemodynamic results between different prostheses
should be based on the patient’s aortic annulus diameter
measured intraoperatively with a neutral instrument, such as
a Hegar dilator. Regarding all patients, there is a significant
superiority in mean pressure gradient of the Perimount
prosthesis at rest (P  .001), which becomes even more
distinct during exercise (P  .001 at 25 W and P  .0001
at 50 W).
Patient-Prosthesis Mismatch
Regarding EOA and EOAI, there is no significant difference
between both valve types. EOAI is an important variable
because it includes EOA, representing the prosthetic hemo-
dynamic performance and body surface area as an indicator
of the patient’s estimated need for performance. EOAI is the
decisive parameter to describe the incidence of patient-
prosthesis mismatch. We rated the extent of patient-pros-
thesis mismatch as not present in patients with an EOAI of
greater than 0.85 cm2/m2, moderate in patients with an
EOAI of 0.85 cm2/m2 or less, and severe in patients with an
EOAI of 0.65 cm2/m2 or less.11 This graduation corresponds
to the general concept that moderate aortic stenosis of a
native valve is present in patients with an EOAI of less than
0.90 cm2/m2.17 Although the aim of aortic valve replace-
ment in patients with aortic stenosis is to remove the ste-
nosis and to realize nearly physiologic transvalvular gradi-
ents, a residual stenosis represented by low EOAI is
frequent, especially with small valve sizes. Patient-prosthe-
sis mismatch is present in up to 52% of the patients with a
stented aortic bioprosthesis.18 This corresponds to the inci-
dence of patient-prosthesis mismatch seen in this series with
valve sizes 23 and 25. Because patient-prosthesis mismatch
might be associated with higher pressure gradients, less LV
and Cardiovascular Surgery ● Volume 129, Number 5 1061
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various strategies to reduce the incidence of mismatch were
introduced: aortic root enlargement, stentless bioprostheses,
and full root replacement. The application of aortic root
enlargement procedures must be recommended, especially
for patients with an aortic annulus that would only allow the
implantation of a size 19 valve. In this series there is a
mismatch in 100% of the patients with a size 19 valve.
Thus, neither a bovine nor porcine stented bioprosthesis of
size 19 can be recommended for implantation, apart from
patients with increased risk for aortic root enlargement or
with such a small body surface area that mismatch does not
occur.
Left Ventricular Mass Regression
All patients in our series showed a regression in LV mass
and mass index, irrespective of prosthesis size, although a
significance in t test results was only seen with the size 23
bovine and the size 25 porcine valves. There was no sig-
nificant difference between both valve types regarding the
absolute amount of LV mass regression. Although there was
a clear reduction in LV mass, the average postoperative LV
mass index for the entire series remained greater than nor-
mal in 34.9% of the patients, with LV hypertrophy defined
as an LV mass index of greater than 130 g/m2 in male
subjects and greater than 100 g/m2 in female subjects.22
Similar observations have been made in other studies of
various heart valve devices.23-25 The reasons for incomplete
regression of hypertrophy include a residual aortic gradient
caused by patient-prosthesis mismatch, persistent high
blood pressure, and nonhemodynamic factors, such as ge-
notype.25 Preoperative LV mass in patients with aortic
stenosis is markedly increased. The magnitude of absolute
LV mass index regression is closely related to preoperative
LV mass index.26 In our series the correlation between
preoperative LV mass index and postoperative LV mass
reduction was an r value of 0.74 (r2  0.55, P  .01).
Conclusions
Both the porcine and the bovine prostheses showed satis-
factory hemodynamic results at rest and during exercise.
The bovine bioprosthesis was significantly superior when
mean pressure gradients were compared in small valve sizes
(21 and 23 mm), and this difference was even more obvious
during exercise at 25 and 50 W. However, geometric dif-
ferences have to be considered between both prostheses,
with the Mosaic prosthesis being generally smaller than the
Perimount prosthesis. Nevertheless, when summarizing all
valve sizes, the aortic annulus diameter was equal in both
groups, and the pressure gradients were significantly lower
in the bovine group.
We recommend that the pressure gradients obtained dur-
ing stress echocardiography be referred to the stroke volume
1062 The Journal of Thoracic and Cardiovascular Surgery ● Mainstead of cardiac output because cardiac output is strongly
influenced by increasing heart rate in elderly patients during
exercise.
Patient-prosthesis mismatch is a common complication
in aortic valve replacement with small valve sizes. This
experience was confirmed in this series without significant
differences between both valve types. Mismatch was
present in 100% of the patients with valve size 19, and thus
aortic root enlargement procedures and implantation of a
larger valve should be recommended instead of implanta-
tion of a valve labeled size 19.
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